Join to View Full Profile
2000 Circle of Hope DriveResearch North 2166Salt Lake City, UT 84103
Phone+1 801-213-3718
Dr. Hu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018
University of Pennsylvania Health SystemResidency, Internal Medicine, 2012 - 2015
Case Western Reserve University School of MedicineClass of 2012
Certifications & Licensure
UT State Medical License 2018 - 2026
TX State Medical License 2015 - 2018
PA State Medical License 2012 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma Start of enrollment: 2019 Jun 24
Roles: Principal Investigator, Contact
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2021 Mar 29
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era.Andrew L Pierce, Izel Okcu, Grzegorz Nowakowski, Seda Tolu, Jennifer Amengual
Journal of the National Comprehensive Cancer Network. 2025-03-28 - 1 citationsLoncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
Haematologica. 2025-03-01 - 4 citationsSafety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBAL...Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain
The Lancet. Oncology. 2025-01-01
Abstracts/Posters
- Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I StudyBoyu Hu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center AnalysisBoyu Hu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
